Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects

NCT05905068 | Completed Phase 1

• 1 other identifier: RN0191-101
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

Objectives: The primary and secondary objectives of the study are presented below. Exploratory objectives are presented in the body of the protocol. Primary:

• To determine the safety and tolerability of RN0191 administered as escalating single subcutaneously (SC) doses in adult subjects with elevated low-density lipoprotein-cholesterol Secondary:
• To evaluate the single-dose pharmacokinetics (PK) of RN0191 in adult subjects with elevated low-density lipoprotein-cholesterol
• To evaluate the pharmacodynamic (PD) effect of RN0191 on serum levels of low-density lipoprotein-cholesterol (LDL-C)
• To evaluate the PD effect of RN0191 on plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Conditions

To Reduce the LDL-C Level in Hypercholesteremia Adult Patients; Combination for Subgroup High LDL-c Patients With Other Comorbidities

Outcome Measures

Primary Outcomes (1)

• Exploratory objectives are presented in the body of the protocol.

  • To determine the safety and tolerability of RN0191 administered as escalating single subcutaneously (SC) doses in adult subjects with elevated low-density lipoprotein-cholesterol

  For each subject in the study, the duration of the study clinic visits is approximately 21 weeks from screening to Day 85/EOS examination.

Study Arms (4)

Cohort 1 will be 25 mg RN0191 (or placebo)

ACTIVE COMPARATOR

Drug: RN0191 INJECTION

Cohort 1 will be 100 mg RN0191 (or placebo)

ACTIVE COMPARATOR

Drug: RN0191 INJECTION

Cohort 1 will be 300 mg RN0191 (or placebo)

ACTIVE COMPARATOR

Drug: RN0191 INJECTION

Cohort 1 will be 500 mg RN0191 (or placebo)

ACTIVE COMPARATOR

Drug: RN0191 INJECTION

Interventions

RN0191 INJECTION DRUG

a sterile solution in each bottle for subcutaneous (SC) injection

Cohort 1 will be 100 mg RN0191 (or placebo); Cohort 1 will be 25 mg RN0191 (or placebo); Cohort 1 will be 300 mg RN0191 (or placebo); Cohort 1 will be 500 mg RN0191 (or placebo)

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male and female subjects, aged 18 to 60 years, inclusive.
• Body mass index between 18 and 32 kg/m2, inclusive, with body weight \> 45 kg for females and \>50 kg for males.
• Serum LDL-C ≥100mg/dL (2.6 mmol/L) at screening and Day -1.
• Fasting triglycerides \< 400 mg/dL (\<4.52 mmol/L) at screening and Day -1.
• Adequate complete blood counts (complete blood counts \[CBCs\]; if outside the reference range, CBC values that are not clinically relevant and are acceptable to the Investigator)
• Female subjects are eligible to participate if they are confirmed either not women of child-bearing potential (WOCBP), or have a negative urine pregnancy test at Day 1, are not breastfeeding, and willing and able to abide by the contraception guidelines.
• Male subjects who can produce viable sperm are eligible to participate if they agree to use an adequate method of contraception as per the contraceptive guidance from Screening (signing the ICF) until at least 3 months post dose. Subjects with a partner(s) who is (are) not of childbearing potential are exempt from these requirements.
• Male subjects with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration. In addition, male subjects must refrain from donating sperm from Screening (signing the ICF) until at least 3 months post dose.
• Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent

You may not qualify if:

• Male and female subjects, aged 18 to 60 years, inclusive.
• Body mass index between 18 and 32 kg/m2, inclusive, with body weight \> 45 kg for females and \>50 kg for males .
• Serum LDL-C ≥100mg/dL (2.6 mmol/L) at screening and Day -1.
• Fasting triglycerides \< 400 mg/dL (\<4.52 mmol/L) at screening and Day -1.
• Adequate complete blood counts (complete blood counts \[CBCs\]; if outside the reference range, CBC values that are not clinically relevant and are acceptable to the Investigator).
• Female subjects are eligible to participate if they are confirmed either not women of child-bearing potential (WOCBP), or have a negative urine pregnancy test at Day 1, are not breastfeeding, and willing and able to abide by the contraception guidelines (signing the ICF).
• Male subjects who can produce viable sperm are eligible to participate if they agree to use an adequate method of contraception as per the contraceptive guidance in Appendix 3 from Screening (signing the ICF) until at least 3 months post dose. Subjects with a partner(s) who is (are) not of childbearing potential are exempt from these requirements.
• Male subjects with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration. In addition, male subjects must refrain from donating sperm from Screening (signing the ICF) until at least 3 months post dose.
• Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent.

Sponsors & Collaborators

• Ikaria Bioscience Pty Ltd: lead

Study Sites (1)

Nucleus Networks

Herston, Brisbane, 4006, Australia

Location

Study Officials

• Kristi McLendon, MD

  Nucleus Network

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated low-density lipoprotein-cholesterol. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study. In this SAD study, adult subjects with elevated LDL-C will be enrolled in up to 4 cohorts. Each cohort will comprise 8 subjects randomized in a 3:1 ratio (1:1 ratio for sentinel subjects; 5:1 ratio for non-sentinel subjects) to receive a single dose of RN0191 (n=6) or placebo (n=2), respectively.

Study Record Dates

• First Submitted: June 2, 2023
• First Posted: June 15, 2023
• Study Start: July 14, 2023
• Primary Completion: February 24, 2024
• Study Completion: May 14, 2024
• Last Updated: October 10, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)